Supportive Care


Xgeva Reduces Bone Complications From Prostate Cancer (02-25-2011)

Among men with bone metastases from prostate cancer, Xgeva™ (denosumab) was more effective than Zometa® (zoledronic acid) at delaying or preventing bone complications such as fracture. Results from this Phase III clinical trial were published in The... Continue Reading

ASCO Calls for Improved Palliative Care (02-9-2011)

The American Society of Clinical Oncology (ASCO) has released a new policy statement that calls for improvement of quality of life among patients with advanced disease (defined here as incurable disease). Specifically, these measures aim to increase... Continue Reading

Social Support May Improve Breast Cancer Outcomes (01-26-2011)

Social well-being during the first year after a breast cancer diagnosis may have a beneficial effect on cancer outcomes. These results were published in the Journal of Clinical Oncology. A diagnosis of breast cancer often affects a woman’s quality of... Continue Reading

Behavioral Therapy Reduces Incontinence after Prostatectomy (01-17-2011)

Behavioral therapy with pelvic floor muscle exercises, bladder control techniques, and fluid management can reduce (but rarely eliminate) urinary incontinence after radical prostatectomy for early prostate cancer. These results were published in the... Continue Reading

Xgeva Delays Bone Complications in Women with Metastatic Breast Cancer (12-21-2010)

In a study of women with bone metastases from breast cancer, Xgeva™ (denosumab) delayed bone complications for five months longer than Zometa® (zoledronic acid). These updated results from a Phase III clinical trial were presented at the 2010 San Antonio... Continue Reading

Nplate Active for More than Five Years in Adults with Chronic ITP (12-13-2010)

Nplate® (romiplostim) appears to maintain platelet counts among adult patients with chronic immune (idiopathic) thrombocytopenia purpura (ITP) for more than five years. These results were presented at the 52nd Annual Meeting and Exposition of the American... Continue Reading

Xgeva Approved for Patients with Bone Metastases (11-30-2010)

Xgeva™ (denosumab) has been approved by the US Food and Drug Administration (FDA) for the prevention of bone complications such as fracture in patients with bone metastases from solid (not blood-related) cancers. It is not approved for patients with... Continue Reading

Denosumab Delays Bone Complications in Women with Metastatic Breast Cancer (11-23-2010)

Among women with bone metastases from breast cancer, denosumab may be more effective than Zometa® (zoledronic acid) at delaying or preventing bone complications such as fracture. The results of this Phase III clinical trial were published in the Journal... Continue Reading

Nplate Reduces Treatment Failure and Splenectomy in Patients with ITP (11-17-2010)

Compared with standard therapies, Nplate® (romiplostim) appears to reduce the risk of treatment failure and need for splenectomy among adult patients with chronic immune thrombocytopenia (ITP). These results were published in the New England Journal... Continue Reading

Memory Problems More Common Among Cancer Survivors (10-27-2010)

People with a history of cancer appear to be 40% more likely to experience memory problems than people with no history of cancer. These findings were recently presented at the Third American Association for Cancer Research Conference on The Science of... Continue Reading

« Previous PageNext Page »